1-4 of 4
David J. Propper
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant Melanoma

David J. Propper, David Chao, Jeremy P. Braybrooke, Pru Bahl, Parames Thavasu, Frances Balkwill, Helen Turley, Nicola Dobbs, Kevin Gatter, Denis C. Talbot, Adrian L. Harris, Trivadi S. Ganesan
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (1): 84–92.
Published: 01 January 2003
View article titled, Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant Melanoma
Open the PDF for Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant Melanoma in another window
Journal Articles

Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer

Nicola C. Levitt, Ferry A. L. M. Eskens, Ken J. O’Byrne, David J. Propper, Louis J. Denis, Samantha J. Owen, Les Choi, John A. Foekens, Sue Wilner, Jeanette M. Wood, Motowo Nakajima, Denis C. Talbot, William P. Steward, Adrian L. Harris, Jaap Verweij
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 1912–1922.
Published: 01 July 2001
View article titled, Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer
Open the PDF for Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer in another window
Journal Articles

A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis

Jeremy P. Braybrooke, Kenneth J. O’Byrne, David J. Propper, Andrew Blann, Mark Saunders, Nicola Dobbs, Cheng Han, Jane Woodhull, Karen Mitchell, Jeremy Crew, Kenneth Smith, Ross Stephens, Trivadi S. Ganesan, Denis C. Talbot, Adrian L. Harris
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (12): 4697–4704.
Published: 01 December 2000
View article titled, A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis
Open the PDF for A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis in another window
Journal Articles

Phase I Study of the Novel Cyclic AMP (cAMP) Analogue 8-Chloro-cAMP in Patients with Cancer: Toxicity, Hormonal, and Immunological Effects

David J. Propper, Mark P. Saunders, Amanda J. Salisbury, Louise Long, Ken J. O’Byrne, Jeremy P. Braybrooke, Mitchell Dowsett, Marion Taylor, Denis C. Talbot, Trivadi S. Ganesan, Adrian L. Harris
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (7): 1682–1689.
Published: 01 July 1999
View article titled, Phase I Study of the Novel Cyclic AMP (cAMP) Analogue 8-Chloro-cAMP in Patients with Cancer: Toxicity, Hormonal, and Immunological Effects
Open the PDF for Phase I Study of the Novel Cyclic AMP (cAMP) Analogue 8-Chloro-cAMP in Patients with Cancer: Toxicity, Hormonal, and Immunological Effects in another window